129 related articles for article (PubMed ID: 21502001)
1. Influence of Simulated Gastrointestinal Fluids on Polymorphic Behavior of Anhydrous Carbamazepine Form III and Biopharmaceutical Relevance.
Bhise SB; Rajkumar M
PDA J Pharm Sci Technol; 2010; 64(1):28-36. PubMed ID: 21502001
[TBL] [Abstract][Full Text] [Related]
2. Surfactant-facilitated crystallization of dihydrate carbamazepine during dissolution of anhydrous polymorph.
Rodríguez-Hornedo N; Murphy D
J Pharm Sci; 2004 Feb; 93(2):449-60. PubMed ID: 14705201
[TBL] [Abstract][Full Text] [Related]
3. Investigation of intrinsic dissolution behavior of different carbamazepine samples.
Sehić S; Betz G; Hadzidedić S; El-Arini SK; Leuenberger H
Int J Pharm; 2010 Feb; 386(1-2):77-90. PubMed ID: 19900519
[TBL] [Abstract][Full Text] [Related]
4. Towards a universal dissolution medium for carbamazepine.
El-Massik MA; Abdallah OY; Galal S; Daabis NA
Drug Dev Ind Pharm; 2006 Aug; 32(7):893-905. PubMed ID: 16908426
[TBL] [Abstract][Full Text] [Related]
5. Solution-mediated phase transformation of anhydrous to dihydrate carbamazepine and the effect of lattice disorder.
Murphy D; Rodríguez-Cintrón F; Langevin B; Kelly RC; Rodríguez-Hornedo N
Int J Pharm; 2002 Oct; 246(1-2):121-34. PubMed ID: 12270615
[TBL] [Abstract][Full Text] [Related]
6. Improving Dissolution Rate of Carbamazepine-Glutaric Acid Cocrystal Through Solubilization by Excess Coformer.
Yamashita H; Sun CC
Pharm Res; 2017 Dec; 35(1):4. PubMed ID: 29288433
[TBL] [Abstract][Full Text] [Related]
7. Influence of polymorphic form, morphology, and excipient interactions on the dissolution of carbamazepine compacts.
Tian F; Sandler N; Aaltonen J; Lang C; Saville DJ; Gordon KC; Strachan CJ; Rantanen J; Rades T
J Pharm Sci; 2007 Mar; 96(3):584-94. PubMed ID: 17080412
[TBL] [Abstract][Full Text] [Related]
8. A New Extrudable Form of Hypromellose: AFFINISOL™ HPMC HME.
Huang S; O'Donnell KP; Keen JM; Rickard MA; McGinity JW; Williams RO
AAPS PharmSciTech; 2016 Feb; 17(1):106-19. PubMed ID: 26335416
[TBL] [Abstract][Full Text] [Related]
9. Increased dissolution rates of carbamazepine--gluconolactone binary blends processed by hot melt extrusion.
Moradiya HG; Nokhodchi A; Bradley MS; Farnish R; Douroumis D
Pharm Dev Technol; 2016; 21(4):445-52. PubMed ID: 25757644
[TBL] [Abstract][Full Text] [Related]
10. Solvent-mediated solid phase transformations of carbamazepine: Effects of simulated intestinal fluid and fasted state simulated intestinal fluid.
Lehto P; Aaltonen J; Tenho M; Rantanen J; Hirvonen J; Tanninen VP; Peltonen L
J Pharm Sci; 2009 Mar; 98(3):985-96. PubMed ID: 18661533
[TBL] [Abstract][Full Text] [Related]
11. Effects of Coformer and Polymer on Particle Surface Solution-Mediated Phase Transformation of Cocrystals in Aqueous Media.
Omori M; Watanabe T; Uekusa T; Oki J; Inoue D; Sugano K
Mol Pharm; 2020 Oct; 17(10):3825-3836. PubMed ID: 32870691
[TBL] [Abstract][Full Text] [Related]
12. Variability in commercial carbamazepine samples--impact on drug release.
Flicker F; Eberle VA; Betz G
Int J Pharm; 2011 May; 410(1-2):99-106. PubMed ID: 21435386
[TBL] [Abstract][Full Text] [Related]
13. The effect of egg albumin on the crystalline properties of carbamazepine in sustained release hydrophilic matrix tablets and in aqueous solutions.
Katzhendler I; Azoury R; Friedman M
J Control Release; 2000 Apr; 65(3):331-43. PubMed ID: 10699292
[TBL] [Abstract][Full Text] [Related]
14. Solid dispersion of carbamazepine in PVP K30 by conventional solvent evaporation and supercritical methods.
Sethia S; Squillante E
Int J Pharm; 2004 Mar; 272(1-2):1-10. PubMed ID: 15019063
[TBL] [Abstract][Full Text] [Related]
15. Physicochemical characterization of solid dispersions of carbamazepine formulated by supercritical carbon dioxide and conventional solvent evaporation method.
Sethia S; Squillante E
J Pharm Sci; 2002 Sep; 91(9):1948-57. PubMed ID: 12210042
[TBL] [Abstract][Full Text] [Related]
16. Dissolution rate enhancement and physicochemical characterization of carbamazepine-poloxamer solid dispersions.
Medarević DP; Kachrimanis K; Mitrić M; Djuriš J; Djurić Z; Ibrić S
Pharm Dev Technol; 2016; 21(3):268-76. PubMed ID: 25582577
[TBL] [Abstract][Full Text] [Related]
17. Investigation of the effect of hydroxypropyl methylcellulose on the phase transformation and release profiles of carbamazepine-nicotinamide cocrystal.
Li M; Qiu S; Lu Y; Wang K; Lai X; Rehan M
Pharm Res; 2014 Sep; 31(9):2312-25. PubMed ID: 24590881
[TBL] [Abstract][Full Text] [Related]
18. Physicochemical and mechanical properties of carbamazepine cocrystals with saccharin.
Rahman Z; Samy R; Sayeed VA; Khan MA
Pharm Dev Technol; 2012; 17(4):457-65. PubMed ID: 21265708
[TBL] [Abstract][Full Text] [Related]
19. In situ monitoring of carbamazepine-nicotinamide cocrystal intrinsic dissolution behaviour.
Qiao N; Wang K; Schlindwein W; Davies A; Li M
Eur J Pharm Biopharm; 2013 Apr; 83(3):415-26. PubMed ID: 23159709
[TBL] [Abstract][Full Text] [Related]
20. Effect of surface modification on hydration kinetics of carbamazepine anhydrate using isothermal microcalorimetry.
Otsuka M; Ishii M; Matsuda Y
AAPS PharmSciTech; 2003; 4(1):E5. PubMed ID: 12916915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
